Efficacy and tolerability of drugs for treatment of benign prostatic hyperplasia

ISSN： 0301-1623

Source： International Urology and Nephrology, Vol.32, Iss.3, 2001-09, pp. : 423-432

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Future drugs for the treatment of benign prostatic hyperplasia

By Andersson Karl-Erik Chapple C. Höfner K.

World Journal of Urology, Vol. 19, Iss. 6, 2002-04 ,pp. : 436-442

Springer Publishing Company

Access to resources Recommend Favorite

Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial

By Kirby R.S. Roehrborn C. Boyle P. Bartsch G. Jardin A. Cary M.M. Sweeney M. Grossman E.B. Predict Study Investigators

Urology, Vol. 61, Iss. 1, 2003-01 ,pp. : 119-126

Elsevier

Access to resources Recommend Favorite

Laser treatment of benign prostatic hyperplasia

By Kuntz Rainer

World Journal of Urology, Vol. 25, Iss. 3, 2007-06 ,pp. : 241-247

Springer Publishing Company

Access to resources Recommend Favorite

Lasers in the treatment of benign prostatic hyperplasia

By Gerber G.S.

Urology, Vol. 45, Iss. 2, 1995-02 ,pp. : 193-199

Elsevier

Access to resources Recommend Favorite

Safety and Tolerability of the Dual 5 -Reductase Inhibitor Dutasteride in the Treatment of Benign Prostatic Hyperplasia

By Andriole G.L. Kirby R.

European Urology, Vol. 44, Iss. 1, 2003-07 ,pp. : 82-88

Elsevier

Access to resources Recommend Favorite